Dare Bioscience Details Nationwide Launch of Sildenafil Cream, Advances HPV Program
DARE is trading near its 52-week low of $1.61 (4.3% above the low).
Summary
Dare Bioscience announced the nationwide availability of its DARE to PLAY Sildenafil Cream and the IND clearance for its DARE-HPV program, advancing both commercial and clinical pipelines.
Key Events · Product Development and Regulatory · DARE
-
Nationwide Prescription Acceptance for Sildenafil Cream
The company's DARE to PLAY Sildenafil Cream is now accepting prescriptions nationwide in the U.S. as a compounded drug through a 503B-registered outsourcing facility partner, as detailed in its updated corporate presentation.
-
DARE-HPV Program Advances to Phase 2
The Investigational New Drug (IND) application for DARE-HPV, an antiviral vaginal insert for persistent high-risk HPV infection, was cleared in February 2026, enabling the initiation of a planned Phase 2 clinical study.
-
Updated Corporate Presentation Released
Dare Bioscience made an updated corporate presentation available on its website, outlining recent and upcoming catalysts, including the Q1 2026 telehealth launches for DARE to PLAY Sildenafil Cream and the Q4 2025 target launch of DARE to RESTORE vaginal probiotics.
Analysis · DARE · Life Sciences
Dare Bioscience, a small-cap life sciences company, announced significant progress in its product pipeline and commercialization efforts. The company's DARE to PLAY Sildenafil Cream is now accepting prescriptions nationwide as a compounded drug, marking a crucial step in its commercial strategy. Additionally, the Investigational New Drug (IND) application for DARE-HPV was cleared in February 2026, allowing the initiation of a planned Phase 2 clinical study. These developments provide positive momentum for the company, especially as it trades near its 52-week low, potentially offering a catalyst for investor sentiment.
At the time of this filing, DARE was trading at $1.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $1.61 to $9.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.